Published on: 15 December 2020 Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Switzerland for people with NTRK fusion-positive solid tumours and for people with ROS1 fusion-positive advanced non-small cell lung cancer more
Subscribe to Roche Media Releases for Switzerland Get the latest news and updates to your inbox. more